Archive for EMBRYONIC

Growth in adult stem cells – Finance

Posted in ALL ARTICLES, BUSINESS OF STEM CELLS with tags , , , , , , , on April 2, 2009 by David Granovsky
Nuvasive (NUVA): Growth in adult stem cells
Thursday, 02 April 2009
 “In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products,” notes growth stock specialist Dave Dyer.

In his Dave Dyer’s Newsletter, he explains, “In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity.” Here, he looks at NuVasive (NASDAQ: NUVA).

“Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

“NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

“This is one of the first regular commercial application of a product based on human stem cells. We note that this product is based on adult stem cells from bone marrow, not embryonic stem cells.

“Osteocel, was sold to NuVasive by Osiris in exchange for a stream of payments based on specific milestones. Nuvasive expects Osteocel to provide $28 million of new revenue for NUVA in 2009, up from $10 million in 2008, so this is a serious product.

“The spinal fusion market — NUVA’s focus — is about $4.2 billion per year. They are a small player, with about 6% of the market, but that is up from 4% last year, for a 50% increase in market share. Not too bad.

“NUVA’s products support a type of minimally-invasive back surgery in which small incisions are made in the side rather than large ones in the back. It provides surgeons with a combination of technology, software, and consumables that bring in about $12,000 per operation.

“Many of their products are based on proprietary patent-protected technology. They have 52 U.S. patents issued and 189 pending.

“Overall, their approach results in less time in the operating room, shorter hospital stays, and faster recovery.  That is probably why they are growing so rapidly. For the last eight quarters, revenue has grown between 50% and 70% per quarter.

“While profits have not grown as rapidly, both 2007 and 2008 were profitable years. In addition, they have no debt.

“A long term chart shows that they had a super 450% gain after their IPO in 2004, but were brought down by the recent bad market. There does not seem to be any fundamental reason behind the drop. It appears that NUVA is now moving in the right direction again.”

TRAIL BLAZERS Blog | The Dallas Morning News

Posted in ALL ARTICLES, STEM CELLS IN THE NEWS with tags , , , , , , , , , , on April 1, 2009 by David Granovsky

senateSenate to kick embryonic stem cell fight to budget conferees

1:29 PM Wed, Apr 01, 2009

CAPITOL ALMANAC.JPGThe Senate decided to punt the embryonic stem cell research controversy to House-Senate budget negotiators, according to Sen. Kip Averitt, R-Waco.

In their lunchtime huddle behind closed doors, senators decided not to try to rewrite today the embryonic stem cell research funding ban, Averitt said. As passed by the Finance Committee, 6-5, last week, the provision bars using funds in the budget for research that involves destruction of human embryos. Averitt said had he been present last week, he would have voted against and the provision would have died on a tie vote — assuming Ogden couldn’t find another “aye” vote.

Also being sent on to conferees, and not fixed on the floor today: A provision that would expand a managed care approach in Medicaid, to rural areas. It supposedly would save the state $7 million but would cost safety net hospitals in rural Texas as much as $200 million in federal matching funds for hospitals treating a lot of poor, uninsured people.

via TRAIL BLAZERS Blog | The Dallas Morning News.

Oz slams the door on embryonics!

Posted in ALL ARTICLES, STEM CELLS IN THE NEWS with tags , , , , , , , , , on April 1, 2009 by David Granovsky

baby_stepsOz slams the door on embryonics!

3 times I have fielded understandable questions from very wise people who want to know why Dr Oz did not go into detail about adult stem cells and iPS cells.  Here is my answer to them.

“you have to understand that you know more about stem cells than 99% of the people in the US.  to them , stem cells = embryos = babies.  as far as they know, there are no other stem cells.

walk down the street and ask someone what an adult stem cell is.  ask them what an iPS cell is.  you will only get blank stares.

what Oz did was truly amazing.  shunning history, media, obama’ s funding, the FDA and the AMA…not to mention the fruitless decade long pursuit of embryonic cures undertaken by the always cute michael j fox with the shadow of chris reeves hovering over him…

Oz slammed the door on embryonics.

one step at a time we will educate the masses and introduce them to the fact that adult stem cells have been treating diseases around the world successfully for a decade.  one step at a time…and this was a huge first step!

So from where I am sitting, I want to express a huge amount of appreciation for what he did.  Thank you Dr Oz!

World’s Leading Scientists Meet to Examine Barriers for Stem Cell Therapies to Cure Spinal Cord Injury

Posted in ALL ARTICLES, STEM CELLS IN THE NEWS with tags , , , , , , , , on April 1, 2009 by David Granovsky

spinal-cord

World’s Leading Scientists Meet to Examine Barriers for Stem Cell Therapies to Cure Spinal Cord Injury

Following President Barack Obama’s decision to lift the ban on federal funding for embryonic stem cell research, medical and scientific experts will converge at the University of Georgia to discuss how recent advances in stem cell research can be translated into cures for spinal cord injuries.

The second Spinal Cord Workshop, a program of the Bedford Stem Cell Research Foundation, will be held on Saturday, April 4 from 8:30 a.m. to 5:30 p.m. at the Paul D. Coverdell Center for Biomedical and Health Sciences.

Every year close to 11,000 people sustain spinal cord injuries in the United States, while more than 200,000 Americans live each day with a disability caused by them.

“Because spinal cord injury usually occurs in otherwise healthy, young adults, it is an especially attractive candidate for a cure for stem cell therapy,” said Ann Kiessling, director of the Bedford Stem Cell Research Foundation. “The big question is whether a ‘moon shot’ approach will produce a cure, or if there is still too much basic science yet unknown.”

The workshop is hosted by UGA’s Regenerative Bioscience Center. Additional support is provided by the UGA Biomedical and Health Sciences Institute, the Shepherd Center in Atlanta, and Millipore, Inc.

“The University of Georgia is fortunate to team up with the Bedford Foundation to host these leading experts in spinal cord therapies to discuss and develop new paths forward for spinal cord injuries,” said Steven Stice, director of the Regenerative Bioscience Center. “In addition, Georgia’s recent legislation aimed at restricting stem cell research makes this workshop an especially timely one.”

Created in 1996, the Bedford Stem Cell Research Foundation is a Massachusetts-based public charity and biomedical institute that exists to conduct stem cell and related research for diseases and conditions that currently have no cure.

The Regenerative Bioscience Center brings UGA’s expertise, resources and accomplishments in human embryonic stem cell research under one umbrella, while contributing to the University’s educational and outreach missions with student research experiences and public lectures, symposia, and workshops communicating the benefits and risks of regenerative bioscience.

The event serves as a follow-up to the inaugural Spinal Cord Workshop held at UGA in March 2008, titled “Spinal Cord Injury: What Are The Barriers To Cure?”

Workshop faculty this year include:
Hans Keirstead, Ph.D, associate professor of anatomy and neurobiology, University of California at Irvine, Reeve-Irvine Research Center; Douglas Kerr, M.D., Ph.D., associate professor of neurology, molecular biology and immunology, and director, John Hopkins Transverse Myelitis Center; John W. McDonald, M.D., Ph.D., director, International Center for Spinal Cord Injury, Kennedy Krieger Institute; Steven L. Stice, Ph.D., professor, GRA Eminent Scholar, director of the Regenerative Bioscience Center at the University of Georgia and CSO, Aruna Biomedical Inc; Keith Tansey, M.D., Ph.D., director, Spinal Cord Injury Research, Shepherd Center; Scott Wittemore, Ph.D., professor and vice chairman for research, Department of Neurological Surgery, University of Louisville; Wise Young, M.D., Ph.D., professor and chair, Department of Cell Biology and Neuroscience, Rutgers University, and director, W.M. Keck Center for Collaborative Neuroscience.

Registration information for the 2009 workshop, as well as video from the 2008 workshop talks, is available online at: http://www.spinalcordworkshop.org

via PR-USA.net – World’s Leading Scientists Meet to Examine Barriers for Stem Cell Therapies to Cure Spinal Cord Inju.

Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research

Posted in ALL ARTICLES, STEM CELLS IN THE NEWS with tags , , , , , , , , , , on April 1, 2009 by David Granovsky

RSCI’s Chairman expressed his concern that since few people can afford to travel outside the country for medical treatments, America needs to put more focus on approving ultra safe adult stem cell treatments to alleviate the suffering of millions diagnosed with so-called untreatable diseases.

Bangkok, Thailand (PRWEB) March 31, 2009 — Don Margolis, founder of the world’s first stem cell treatment company and chairman of the Repair Stem Cell Institute, today issued a statement which took strong exception to Washington’s emphasis on embryonic stem cells over both Repair (Adult) Stem Cells and induced Pluripotent stem cells (iPS).

Don Margolis - the world's leading Adult Stem Cell advocate Don Margolis – the world’s leading Adult Stem Cell advocate

Margolis said, “This leads to one key question which no one in America seems to ask: Why is the FDA, which indiscriminately rushes unproven deadly drugs to AIDS patients, forbidding six million dying heart patients access to long-proven SAFE stem cell therapy?” Is it because heart patients don’t count in politics while AIDS patients do? Or is there another reason why they allow drugs such as Vioxx and forbid risk-free stem cells?

Margolis added that Repair Stems Cells are right now, every week, improving dozens and dozens of lives all over the world. He emphasized that “Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular dystrophy, ataxia, autism, COPD, emphysema, Crohn’s, and optic nerve disorders, among 100+ other conditions, are receiving successful stem cell treatments today on every continent but North America!”

“When the President lifted the partial ban on federal funding for embryonic stem cell research stem cell research, he did not mention that Embryonic Stem Cells (ESC) have never worked on humans or animals and never will,” Margolis said. “He also didn’t mention that Embryonic Stem Cells, when injected into your body, can cause deadly tumors as they have in thousands of lab animals.”

Mr. Margolis pointed out that just five days before the ESC announcement, Dr. Bernadine Healy, former director of the National Institutes of Health, published an article in U.S. News & World Report which states, “To date, most of the stem cell triumphs that the public hears about involve the infusion of adult stem cells.” Healy concluded that “during the first six weeks of Obama’s term, several events reinforced the notion that embryonic stem cells . . . are obsolete.”

In support of Dr. Healy’s point, Margolis quoted three world-class embryonic research scientists. First was Dr. James Thomson, the godfather of embryonics: “It is more than ironic that the scientist who first isolated and cultured ESC once said ’embryonic stem cells are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.'” Margolis went on to note that “Dr. Thomson’s observation is even truer today. The number of diseases treatable with RSC is rapidly approaching 200, while the ESC count still sits on zero, despite the efforts of a thousand ESC researchers on four continents not hindered by the Bush era regulations.”

Margolis then discussed the recent extraordinary discovery of induced Pluripotent stem cells (iPS), which can easily replace the need for ESC. “The potential of iPS is so big,” Margolis said, “that even Dr. Ian Wilmut, who led the team that cloned the famous Dolly the sheep, abandoned his license to attempt human cloning, stating that researchers ‘may have achieved what no politician could: an end to the embryonic stem cell debate.'”

“And end it we must,” Margolis added, “before billions more dollars are wasted while millions of patients are forced to sit on Death Row, waiting for 21st century alchemy to magically transform embryonic stem cells into repair stem cells.”

In closing, Margolis quoted Dr. Colin McGuckin, a noted UK embryonic research leader at Newcastle U. before departing for more useful RSC research in France: “The best estimates of the embryonic scientists here at Newcastle is that embryonic stem cells may not be able to help people this side of 50 years. That’s my lifetime. We can’t wait that long.'”

Mr. Margolis agrees: “The real cost of embryonic research is not the wasted billions, but 50 more years of unnecessary suffering by those who can be helped today.”

About The Repair Stem Cell Institute: The Repair Stem Cell Institute’s mission is to educate and inform everyone about the rapid advances being made in Repair Stem Cell research, so all can intelligently exercise freedom of choice in medical care. If you, or a loved one, are seeking treatment for your “untreatable” medical condition, visit http://www.repairstemcells.org for our list of the eight most experienced and successful stem cell treatment centers in the world, as well as the standards we apply to them.

via http://www.prweb.com/releases/2009/03/prweb2276914.htm

OPRAH! MICHAEL J FOX! DR MEHMET OZ! THE STEM CELL DEBATE IS DEAD!!

Posted in ALL ARTICLES, BEST OF THE BEST, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES with tags , , , , , , , , , , on March 31, 2009 by David Granovsky

michael-j-fox-oprah-oz1

Dr Mehmet Oz says to Michael J Fox, Oprah & ~7.2 million viewers:

“I think, Oprah, the stem cell debate is dead.”

“The problem with embryonic stem cells is that embryonic stem cells come from embryos, like all of us are made from embryos, and those cells can become any cell in the body, but it’s very hard to control them and so they can become cancer.”

“I can take a little bit of your skin, take those cells, get them to go back in time so they are like they were when you were first made, and then they will start to make that dopamine & I think those cells, because they won’t be as prone to cancer & because they’re your genes will be the ones that are ultimately used to cure Parkinsons.”

“I think we are single digit years away from making a big impact in the lives of Parkinson’s disease but also diabetics, heart disease, people who have had a lot of problems.”

you can see the video here:
http://www.oprah.com/media/20090319-tows-dr-oz-brain

A Grim Fairy Tale – America’s Doomed Love Affair with Embryonic Stem Cell Research – Part 6 – Follow the Money, Not the Science

Posted in ALL ARTICLES with tags , , , , , , , , , , on March 30, 2009 by David Granovsky
romeo & juliet

romeo & juliet

A Six Part Series

by Don Margolis, Founder of the Repair Stem Cell Institute – http://repairstemcells.org
A Grim Fairy Tale – Part 6

There are six reasons why embryonic stem cells will never make it out of the lab and into the bodies of sick Americans.

Reason 6: Follow the Money, not the Science

There is just no way that anyone can make money, in the long run, from the disaster known as embryonics. Sure, in the short run there can be some old boy network exchanges of cash between funders and research facility executives, but once the word got out that embryonic stem cells can cause cancer or destroy immune systems, the money train was diverted, as seen by Geron (GERN) stock: $75 in 2000, $1.95 in 2008 until Wall Street, seeing Obama about to win, started its own profiteering, ripping off investors to the tune of $43,000,000.   See “Geron Marches On” in our March 5 Special Newsletter:

http://repairstemcells.org/CMSModules/Newsletters/CMSPages/GetNewsletterIssue.aspx?issueId=8

The dead end research of embryonics protects the huge profit margins of Big Medicine’s profitable drugs, no matter how deadly (Vioxx et al); profitable medical machines, no matter how toxic (drug eluding stents); profitable tests no matter the risk (mammograms); and profitable hospitalizations, no matter how useless (too numerous to mention). Support for the real cure of RSC could ravage those profits. Small wonder that the money and their controlled media have been attacking the only stem cells that actually work, calling RSC “snake oil.”

As Sharon Begley points out in her recent Newsweek article, “Doctors have long resisted having science guide their practice.” Add to that the list of science-resisting profiteers: pharmaceutical companies, medical device makers, health insurance companies and health management organizations, and it becomes much clearer why ESCs, which will never cure anything and affect profits, have been heavily promoted, while RSCs, which can diminish the current outrageous profits, have been heavily disparaged.   Just another reason why the American Medical System has been proven the worst in the developed world. See “Why Not the Best” at:

http://www.commonwealthfund.org/Content/Publications/Fund-Reports/2008/Jul/Why-Not-the-Best–Results-from-the-National-Scorecard-on-U-S–Health-System-Performance–2008.aspx